Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImaginAb has entered into a partnership with Eurogentec to create a new system for generating engineered antibody fragments.
Subscribe to our email newsletter
The tie up is expected to accelerate the development of ImaginAb’s pipeline of targeted molecular imaging agents for the diagnosis and treatment management of cancer and autoimmune diseases.
ImaginAb CEO Christian Behrenbruch said with their expanding pharma client base worldwide, ImaginAb is leveraging multiple manufacturing technologies to increase the capacity for fast, reliable protein production.
Eurogentec CSO Philippe Cronet said their technology platform is well suited to a variety of recombinant proteins including the important class of antibody fragment proteins such as those under development by ImaginAb.